Wordt geladen...
Docetaxel for the Treatment of Hormone-Refractory Prostate Cancer
Chemotherapy has historically proven toxic and ineffective for the treatment of metastatic hormone-refractory prostate cancer (HRPC), a disease with substantial morbidity and mortality. Progress has been made in symptom relief, and the combination of mitoxantrone and prednisone is considered the pal...
Bewaard in:
| Hoofdauteur: | |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
MedReviews, LLC
2003
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1502348/ https://ncbi.nlm.nih.gov/pubmed/16985945 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|